02346nas a2200325   4500000000100000008004100001260001200042653002200054653001900076653002100095653002600116653003900142653001700181100001800198700002300216700002100239700001800260700002300278700001600301700002000317700001500337700001500352700002100367245013200388856004400520300000700564490000700571520142800578022001402006       2025                            d  bMDPI AG10aTrypanosoma cruzi10aChagas disease10aNon-endemic area10aChagas Cardiomyopathy10aNeglected tropical diseases (NTDs)10aBenznidazole1 aBea-Serrano C1 ade Gracia-León AI1 aLlenas-García J1 aVela-Bernal S1 aBelmonte-Domingo A1 aPinto-Pla C1 aFerrer-Ribera A1 aGalindo MJ1 aAlcaraz MJ1 aOltra Sempere MR00aChagas Disease in a Non-Endemic Setting: Clinical Profile, Treatment Outcomes, and Predictors of Cure in a 15-Year Cohort Study  uhttps://www.mdpi.com/2414-6366/10/6/161  a160 v103 a<jats:p>This retrospective cohort study aimed to assess clinical and epidemiological characteristics, treatment outcomes, and predictors of serological cure in patients with chronic Chagas disease in a non-endemic setting. All individuals aged ≥16 years with confirmed infection and evaluated at a tertiary hospital in Spain from 2008 to 2023 were included. Most of the 107 participants were women (78.5%) and Bolivian-born (99.1%). Digestive and cardiac involvement were identified in 32.7% and 17.8% of cases, respectively. Cardiac symptoms were significantly associated with the diagnostic findings of cardiac involvement (odds ratio [OR] 3.0, 95% confidence interval [CI] 1.1–8.2), whereas digestive symptoms did not correlate with imaging abnormalities (OR 0.7, 95% CI 0.3–1.6). Antiparasitic treatment, usually benznidazole, was initiated in 69% of patients and led to adverse events in 66.2%, with treatment discontinuation in 25.7%. Only 8.1% of treated patients achieved serological cure after a median 26 months, with obesity emerging as the only independent predictor (adjusted OR 31.0, 95% CI 3.7–261.2). Cardiac progression occurred in 9.3% of patients despite treatment. Although 59.8% were lost to follow-up, the cohort maintained a median follow-up of 27 months. These findings underscore the need for improved treatment strategies and sustained clinical monitoring in non-endemic settings.</jats:p>  a2414-6366